Carl Stefan Fraenkel
Direktor/Vorstandsmitglied bei Akinion Pharmaceuticals AB
Aktive Positionen von Carl Stefan Fraenkel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Carl Stefan Fraenkel
Ehemalige bekannte Positionen von Carl Stefan Fraenkel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 23.02.2011 | - |
Ausbildung von Carl Stefan Fraenkel
| Copenhagen Business School | Doctorate Degree |
| Chalmers University of Technology | Undergraduate Degree |
Statistik
International
| Schweden | 4 |
| Dänemark | 2 |
Operativ
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
- Börse
- Insiders
- Carl Stefan Fraenkel
- Erfahrung